A Phase 4 interventional study of Intravenous Treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 27th largest by enrollment, is one of 3 that started in 2005, is one of 14 in phase 4, and was the 31st registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2005.
This study's enrollment of 20 is below the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 28th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2005, is one of 11 in phase 4, and was the 42nd registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intravenous treprostinil was supplied as 1 mg/mL.
Drug: Intravenous Treprostinil
Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
Also known as: Remodulin
Effect of Long-term Remodulin Therapy on the 6-Minute Walk Distance (6MWD)
The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living.
Time frame: The 6MWD was assessed at each subject's last visit, which occurred up to approximately 9 years after first visit
Effect of Long-term Remodulin Therapy on the NYHA Functional Classification
The NYHA functional classification ranges from I (subject's disease does not affect daily activities) to IV (subject's disease causes severe impairment).
Time frame: The NYHA functional classification was assessed at each subject's last visit, which occurred up to approximately 9 years after first visit
Effect of Long-term Remodulin Therapy on Subject Safety
Safety was assessed by summarizing the number of subjects with at least 1 AE during the 12 weeks (or until premature termination).
Time frame: Baseline to Week 12
| Milestone | Intravenous Treprostinil |
|---|---|
| Started | 20 |
| Completed | 0 |
| Not completed | 20 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Death | 6 |
| Withdrew: Physician decision | 1 |
| Withdrew: Study terminated by sponsor | 3 |
| Withdrew: Lost to follow-up | 4 |
The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living.
| Meters | Intravenous Treprostinil |
|---|---|
| Effect of Long-term Remodulin Therapy on the 6-Minute Walk Distance (6MWD) | 440.8 ± 108.6 |
The NYHA functional classification ranges from I (subject's disease does not affect daily activities) to IV (subject's disease causes severe impairment).
| Functional Class | Intravenous Treprostinil |
|---|---|
| Effect of Long-term Remodulin Therapy on the NYHA Functional Classification | 2.1 ± 0.6 |
Safety was assessed by summarizing the number of subjects with at least 1 AE during the 12 weeks (or until premature termination).
| Participants | Intravenous Treprostinil |
|---|---|
| Effect of Long-term Remodulin Therapy on Subject Safety | 14 |
Collected over Baseline to each subject's last visit, assessed up to approximately 9 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravenous Treprostinil | 6/16 (37.5%) | 14/16 (87.5%) | 14/16 (87.5%) |
| Event | Intravenous Treprostinil |
|---|---|
| PyrexiaGeneral disorders | 5/16 |
| Catheter site infectionInfections and infestations | 4/16 |
| Device dislocationGeneral disorders | 3/16 |
| Device-related infectionInfections and infestations | 3/16 |
| BacteraemiaInfections and infestations | 2/16 |
| Device-related sepsisInfections and infestations | 2/16 |
| Pyogenic granulomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/16 |
| SepsisInfections and infestations | 1/16 |
| CoagulopathyBlood and lymphatic system disorders | 1/16 |
| Cardiac failure acuteCardiac disorders | 1/16 |
| Event | Intravenous Treprostinil |
|---|---|
| Abdominal discomfortGastrointestinal disorders | 3/16 |
| NauseaGastrointestinal disorders | 3/16 |
| Catheter site painGeneral disorders | 3/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/16 |
| DiarrhoeaGastrointestinal disorders | 2/16 |
| VomitingGastrointestinal disorders | 2/16 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/16 |
| Pain in jawMusculoskeletal and connective tissue disorders | 2/16 |
| HeadacheNervous system disorders | 2/16 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/16 |
| Age, Continuous(years) | Intravenous Treprostinil |
|---|---|
| Mean | 30.1 ± 10.0 |
| Sex: Female, Male(Participants) | Intravenous Treprostinil |
|---|---|
| Female | 9 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | Intravenous Treprostinil |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Intravenous Treprostinil |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 16 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Intravenous Treprostinil |
|---|---|
| India | 16 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2005 to primary completion in Feb 2014, 104 months.
Results were first posted in Jul 2017, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →